Regeneron Pharmaceuticals (REGN) cash: $3.1B
Regeneron Pharmaceuticals held $3.1B in cash and cash equivalents on Dec 31, 2025, up 25.3% from $2.5B a year earlier.
From Regeneron Pharmaceuticals's filings with the SEC · Read the filing · REGN stock page
Regeneron Pharmaceuticals cash by year
#198 of 4,171 US companies by cash · See the full ranking
| Year ended | Cash | Change |
|---|---|---|
| Dec 31, 2025 | $3.1B | +25% |
| Dec 31, 2024 | $2.5B | -9% |
| Dec 31, 2023 | $2.7B | -12% |
| Dec 31, 2022 | $3.1B | +8% |
| Dec 31, 2021 | $2.9B | – |
Cash of similar companies
Companies in the same industry as Regeneron Pharmaceuticals, by SEC industry code, with the closest cash. Each name opens the same page for that company.
| Company | Cash, latest year | Year ended |
|---|---|---|
| AbbVie | $5.2B | Dec 31, 2025 |
| Vertex Pharmaceuticals Inc / Ma | $5.1B | Dec 31, 2025 |
| BeOne Medicines | $4.5B | Dec 31, 2025 |
| TEVA Pharmaceutical Industries | $3.6B | Dec 31, 2025 |
| Regeneron Pharmaceuticals | $3.1B | Dec 31, 2025 |
| Zoetis | $2.5B | Dec 31, 2025 |
| Alnylam Pharmaceuticals | $1.7B | Dec 31, 2025 |
Questions and answers
What is Regeneron Pharmaceuticals's cash?
Regeneron Pharmaceuticals held $3.1B in cash and cash equivalents on Dec 31, 2025, up 25.3% from $2.5B a year earlier.
Numbers as reported in Regeneron Pharmaceuticals's annual and quarterly reports to the SEC (XBRL data). A year is the company's fiscal year that falls mostly in that calendar year; balances such as cash and debt are as of the date shown. Data only, not investment advice. Methodology